<DOC>
	<DOCNO>NCT01643863</DOCNO>
	<brief_summary>This multi-center observational study evaluate use RoActemra/Actemra ( tocilizumab ) monotherapy patient rheumatoid arthritis . Eligible patient initiated RoActemra/Actemra treatment accord license label follow 6 month .</brief_summary>
	<brief_title>A Non-Interventional Study RoActemra/Actemra ( Tocilizumab ) Monotherapy Patients With Rheumatoid Arthritis ( MONACO )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Moderate severe rheumatoid arthritis accord revise ( 1987 ) ACR criterion Patients treat physician make decision commence RoActemra/Actemra treatment monotherapy , case methotrexate intolerance continuous methotrexate treatment inadequate ( accordance local label ) , receive ( start ) RoActemra/Actemra monotherapy treatment within 8 week prior enrolment visit . Concomitant corticosteroid ( oral intraarticular ) nonsteroidal antiinflammatory drug ( NSAIDs ) allow Patients RoActemra/Actemra contraindicate accord approve Summary Product Characteristics Patients receive RoActemra/Actemra 8 week prior enrolment visit Patients previously receive RoActemra/Actemra clinical trial compassionate use Concomitant DMARD treatment rheumatoid arthritis ( e.g . hydroxychloroquine , sulfasalazine , methotrexate , leflunomide , gold compound , cyclosporine ) start treatment RoActemra/Actemra Treatment investigational agent within 4 week ( 5 halflives investigational agent , whichever long ) start treatment RoActemra/Actemra History autoimmune disease joint inflammatory disease rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>